Neve Cufflin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neve Cufflin has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Iain Parry Hargreaves
School of Pharmacy, Liverpool John Moores University, Liverpool L3 5UA, UK
3 shared publications - David Mantle
Pharma Nord (UK) Ltd., Morpeth NE61 2DB, Northumberland, UK
2 shared publications - David Mantle
Pharma Nord (UK) Ltd., Morpeth NE61 2DB, UK
1 shared publication - Mollie Dewsbury
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK
1 shared publication - Tyler T. Purcell
School of Medical Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK
1 shared publication
Latest Publications
- Open Access
- 15 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3526
Bypass Treatments for Primary Coenzyme Q10 Deficiency: An Update
Primary coenzyme Q10 (CoQ10) deficiency results from mutations in genes involved in the CoQ10 biosynthetic pathway. In humans, at least 10 genes (PDSS1, PDSS2 to COQ10) are required for the biosynthesis of functional CoQ10, a mutation in any one of which can result in a deficit in CoQ10 status and present as primary CoQ10 deficiency. Furthermore, the genes NDUFA9 and HPDL, whilst not part of the PDSS1, PDSS2 to COQ10 gene sequence, have also been shown to have a crucial role in CoQ10 biosynthesis. A major problem in treating primary CoQ10 deficiencies is the poor bioavailability of supplemental CoQ10, both in terms of lack of absorption from the digestive tract and inability to cross the human blood–brain barrier. Bypass strategies aim to circumvent this problem by using more bioavailable precursor analogues that can enter the cell and be incorporated into the CoQ10 synthesis pathway downstream of the affected enzyme, examples being 4-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid or vanillic acid, which, in contrast to CoQ10, are small, water-soluble molecules. In this article, we have, therefore, reviewed potential bypass mechanisms for primary CoQ10 deficiencies, PDSS1, PDSS2 to COQ10, together with NDUFA9 and HPDL, using such precursors. Most of the published data relating to the bypass therapy of primary CoQ10 deficiency is derived from cell lines or animal models, and few human studies have so far been undertaken. In addition, further research is required to investigate the potential mechanisms by which bypass compounds such as 4-HB may access the human blood–brain barrier (BBB), for example, using in vitro co-culture BBB model systems incorporating CoQ10-deficient neurons. Overall, the objective of this article is, therefore, to systematically review the available data for each of the primary CoQ10 deficiencies, PDSS1, PDSS2 to COQ10 together with NDUFA9 and HPDL, in particular to identify the clinical potential of such studies.
- 15 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (8) , 3526
Open AccessBypass Treatments for Primary Coenzyme Q10 Deficiency: An Update
Primary coenzyme Q10 (CoQ10) deficiency results from mutations in genes involved in the CoQ10 biosynthetic pathway. In humans, at least 10 genes (PDSS1, PDSS2 to COQ10) are required for the biosynthesis of functional CoQ10, a mutation in any one of which can result in a deficit in CoQ10 status and present as primary CoQ10 deficiency. Furthermore, the genes NDUFA9 and HPDL, whilst not part of the PDSS1, PDSS2 to COQ10 gene sequence, have also been shown to have a crucial role in CoQ10 biosynthesis. A major problem in treating primary CoQ10 deficiencies is the poor bioavailability of supplemental CoQ10, both in terms of lack of absorption from the digestive tract and inability to cross the human blood–brain barrier. Bypass strategies aim to circumvent this problem by using more bioavailable precursor analogues that can enter the cell and be incorporated into the CoQ10 synthesis pathway downstream of the affected enzyme, examples being 4-hydroxybenzoic acid, 2,4-dihydroxybenzoic acid or vanillic acid, which, in contrast to CoQ10, are small, water-soluble molecules. In this article, we have, therefore, reviewed potential bypass mechanisms for primary CoQ10 deficiencies, PDSS1, PDSS2 to COQ10, together with NDUFA9 and HPDL, using such precursors. Most of the published data relating to the bypass therapy of primary CoQ10 deficiency is derived from cell lines or animal models, and few human studies have so far been undertaken. In addition, further research is required to investigate the potential mechanisms by which bypass compounds such as 4-HB may access the human blood–brain barrier (BBB), for example, using in vitro co-culture BBB model systems incorporating CoQ10-deficient neurons. Overall, the objective of this article is, therefore, to systematically review the available data for each of the primary CoQ10 deficiencies, PDSS1, PDSS2 to COQ10 together with NDUFA9 and HPDL, in particular to identify the clinical potential of such studies.
- Open Access
- 28 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 41
Blood–Brain Barrier and Neuronal Model Systems for Studying CoQ10 Metabolism
The disparity in outcomes between preclinical and clinical studies supplementing coenzyme Q10 (CoQ10) in neurological disorders may be a reflection of the differences in the ability of supplemental CoQ10 to access the blood–brain barrier (BBB) in rodents and in humans, which is, in turn, a consequence of contrasting structures of the BBB. The applicability of in vivo animal models to study access of CoQ10 across the BBB and subsequent neuronal metabolism has, therefore, been questioned, and there is an argument, perhaps surprisingly, that in vitro model systems (particularly 3D cellular systems) may be more appropriate. In this article, we have, therefore, reviewed the role of model systems to study the access of CoQ10 across the BBB, as well as the role of such systems in studying the role of CoQ10 in aspects of neuronal metabolism, such as mitochondrial and lysosomal function. In addition, the use of such model systems to study the interactions of CoQ10 with vitamin E and selenium has been reviewed. Finally, the practical application of a neuronal model system to investigate the effect of CoQ10 supplementation on CoQ10 status and mitochondrial metabolism in a CoQ10 deficiency state has been described.
- 28 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 41
Open AccessBlood–Brain Barrier and Neuronal Model Systems for Studying CoQ10 Metabolism
The disparity in outcomes between preclinical and clinical studies supplementing coenzyme Q10 (CoQ10) in neurological disorders may be a reflection of the differences in the ability of supplemental CoQ10 to access the blood–brain barrier (BBB) in rodents and in humans, which is, in turn, a consequence of contrasting structures of the BBB. The applicability of in vivo animal models to study access of CoQ10 across the BBB and subsequent neuronal metabolism has, therefore, been questioned, and there is an argument, perhaps surprisingly, that in vitro model systems (particularly 3D cellular systems) may be more appropriate. In this article, we have, therefore, reviewed the role of model systems to study the access of CoQ10 across the BBB, as well as the role of such systems in studying the role of CoQ10 in aspects of neuronal metabolism, such as mitochondrial and lysosomal function. In addition, the use of such model systems to study the interactions of CoQ10 with vitamin E and selenium has been reviewed. Finally, the practical application of a neuronal model system to investigate the effect of CoQ10 supplementation on CoQ10 status and mitochondrial metabolism in a CoQ10 deficiency state has been described.
- Open Access
- 15 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6486
Ischaemia–Reperfusion Injury in Organ Transplantation: Role of Coenzyme Q10
The success of organ transplantation can be compromised by ischaemia–reperfusion injury (IRI), an unavoidable consequence of transplant surgery. IRI is associated with mitochondrial dysfunction, oxidative stress, inflammation, and apoptosis/ferroptosis. There is therefore a rationale for supplementation with coenzyme Q10 (CoQ10) to mediate the adverse effects of IRI, given the role of CoQ10 in promoting normal mitochondrial function, as an antioxidant, and as an anti-inflammatory and anti-apoptotic/ferroptotic agent. In this article we have reviewed the potential role of supplementary CoQ10 in organ transplantation in preclinical animal studies based on the above actions; the role of supplementary CoQ10 in promoting stem cell action in transplantation and its role in alleviating the adverse effects of immunosuppressants used in organ transplantation are also discussed.
- 15 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6486
Open AccessIschaemia–Reperfusion Injury in Organ Transplantation: Role of Coenzyme Q10
The success of organ transplantation can be compromised by ischaemia–reperfusion injury (IRI), an unavoidable consequence of transplant surgery. IRI is associated with mitochondrial dysfunction, oxidative stress, inflammation, and apoptosis/ferroptosis. There is therefore a rationale for supplementation with coenzyme Q10 (CoQ10) to mediate the adverse effects of IRI, given the role of CoQ10 in promoting normal mitochondrial function, as an antioxidant, and as an anti-inflammatory and anti-apoptotic/ferroptotic agent. In this article we have reviewed the potential role of supplementary CoQ10 in organ transplantation in preclinical animal studies based on the above actions; the role of supplementary CoQ10 in promoting stem cell action in transplantation and its role in alleviating the adverse effects of immunosuppressants used in organ transplantation are also discussed.